BofA analyst Jason Zemansky raised the firm’s price target on Syndax (SNDX) to $28 from $27 and keeps a Buy rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings “may not have the same impact they’ve had in prior years,” the analyst tells investors in a preview for the firm’s biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
- Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
- Syndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
- Syndax Highlights Strong 2025 Results and Path to Profitability
- Syndax announces expected milestones for 2026